Impact of Hepatitis C Virus Clearance on Cardiovascular Risk: A Real‐World Experience From the Nationwide Taiwan Hepatitis C Virus Registry
The Kaohsiung Journal of Medical Sciences · 2025
DOI: 10.1002/kjm2.70036 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Kaohsiung Journal of Medical Sciences, 2025. Verfasst von Ping-Jen Hu und 42 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Gastroenterology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Hepacivirus, Hepatitis C, Chronic. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Center for Medical informatics and Statistics of Kaohsiung Medical University.
Abstract (Originalsprache)
Hepatitis C virus (HCV) infection is associated with an increased risk of cardiovascular disease (CVD); however, the impact of interferon (IFN)‐based therapy on cardiovascular outcomes remains unclear. This nationwide cohort study included 7411 patients with HCV from The Taiwanese Chronic Hepatitis C Cohort registry who received IFN‐based therapy between 2003 and 2014. Patients were categorized into sustained virological response (SVR) ( n = 5785) and non‐SVR ( n = 1676) groups. The incidence of new‐onset CVD events, including stroke, coronary artery disease, heart failure, and arrhythmia, was assessed using three Cox proportional hazard models adjusted for different sets of confounding factors. The cumulative CVD incidence was comparable in the SVR and non‐SVR groups (11.2% vs. 10.2%, p = 0.609). SVR was not significantly associated with a reduced overall CVD risk among the three models [hazards ratio (HR) = 0.88, 95% confidence interval (CI): 0.71–1.05, p = 0.158]. However, a lower risk of stroke was observed in patients who achieved an SVR, although the difference was not significant (HR = 0.84, 95% CI: 0.74–0.94). The results of the sensitivity analyses confirmed these findings. An SVR following IFN‐based therapy did not substantially reduce the overall CVD risk; however, a potential reduction in stroke risk was observed. These results emphasize the importance of long‐term cardiovascular risk assessments and highlight the need for further research, particularly in the direct‐acting antiviral era in which increased cardiovascular benefits may be expected.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Gastroenterology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
- Hepatobiliary Section, Department of Internal Medicine, and Hepatitis Center, Kaohsiung Medical University Hospital; Hepatitis Research Center, School of Medicine and Cohort Research Center, Kaohsiung Medical University…
- Department of Internal Medicine, Chiayi Christian Hospital, Chiayi, Taiwan.
- Division of Hepatogastroenterology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan.
- Division of Hepatogastroenterology, Department of Internal Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan.
- Department of Gastroenterology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan.
ORCID-Profile: Ping-Jen Hu, Pei-Chien Tsai, Chao-Hung Hung, Hsueh-Chou Lai, Cheng-Yuan Peng, Chen-Hua Liu, Chi-Ming Tai, Ming-Lun Yeh, Chung-Feng Huang, Jee-Fu Huang, Yen-Hsiange Wang, Ming-Lung Yu
Förderung
- Center for Medical informatics and Statistics of Kaohsiung Medical University
Zitieren
APA
Hu, P. J., Tsai, P. C., Chen, C. Y., Kuo, H. T., Hung, C. H., Tseng, K. C., Lai, H. C., Peng, C. Y., Wang, J. H., Chen, J. J., Lee, P. L., Chien, R. N., Yang, C. C., Lo, G. H., Kao, J. H., Liu, C. J., Liu, C. H., Yan, S. L., Lin, C. Y., …, & T‐COACH Study Group (2025). Impact of Hepatitis C Virus Clearance on Cardiovascular Risk: A Real‐World Experience From the Nationwide Taiwan Hepatitis C Virus Registry. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.70036
Vancouver
Hu PJ, Tsai PC, Chen CY, Kuo HT, Hung CH, Tseng KC, et al. Impact of Hepatitis C Virus Clearance on Cardiovascular Risk: A Real‐World Experience From the Nationwide Taiwan Hepatitis C Virus Registry. The Kaohsiung Journal of Medical Sciences. 2025. doi:10.1002/kjm2.70036
BibTeX
@article{Hu2025,
author = {Hu, Ping-Jen and Tsai, Pei-Chien and Chen, Chi-Yi and Kuo, Hsing-Tao and Hung, Chao-Hung and Tseng, Kuo-Chih and Lai, Hsueh-Chou and Peng, Cheng-Yuan and Wang, Jing-Houng and Chen, Jyh-Jou and Lee, Pei-Lun and Chien, Rong-Nan and Yang, Chi-Chieh and Lo, Gin-Ho and Kao, Jia-Horng and Liu, Chun-Jen and Liu, Chen-Hua and Yan, Sheng-Lei and Lin, Chun-Yen and Su, Wei-Wen and Chu, Cheng-Hsin and Chen, Chih-Jen and Tung, Shui-Yi and Tai, Chi-Ming and Lin, Chih-Wen and Lo, Ching-Chu and Cheng, Pin-Nan and Chiu, Yen-Cheng and Wang, Chia-Chi and Cheng, Jin-Shiung and Tsai, Wei-Lun and Lin, Han-Chieh and Huang, Yi-Hsiang and Yeh, Ming-Lun and Huang, Chung-Feng and Hsieh, Meng-Hsuan and Huang, Jee-Fu and Dai, Chia-Yen and Chung, Wan-Long and Wang, Yen-Hsiange and Yu, Ming-Lung and Bair, Ming-Jong and T‐COACH Study Group, T‐COACH Study Group},
title = {Impact of Hepatitis C Virus Clearance on Cardiovascular Risk: A Real‐World Experience From the Nationwide Taiwan Hepatitis C Virus Registry},
journal = {The Kaohsiung Journal of Medical Sciences},
year = {2025},
doi = {10.1002/kjm2.70036}
}
EUVIMED